Series A Health & Wellness Funders

Acumen is a venture philanthropy organization that invests in visionary entrepreneurs building transformational companies from seed to scale. They focus on funding bold entrepreneurs who are creating inclusive solutions across sectors like sustainable agriculture, quality education, renewable energy, healthy communities, dignified jobs, and gender equality. Their mission is to break the cycle of poverty through patient capital investments in high-innovation, high-impact enterprises. They operate by deploying philanthropic capital to shape markets and support entrepreneurs who are addressing the world's toughest poverty-related challenges, investing where traditional funders won't. Acumen Ventures has established itself as a significant force in the impact investing ecosystem since 2001, with an A to Z directory of portfolio companies spanning over two decades. They matter because they've reinvented the rules of return, prioritizing impact alongside financial sustainability and helping to demonstrate that venture philanthropy can drive meaningful systemic change in underserved communities globally.

Angelini Ventures is the venture capital arm of Angelini Industries, investing in innovative startups across biotech and digital health. The firm focuses on advancing healthcare through breakthrough therapies, medical technologies, and data-driven solutions. With a global investment strategy, Angelini Ventures backs early and growth-stage companies working to improve patient outcomes and transform how diseases are treated and managed. The firm combines capital with deep industry expertise and strategic support from its parent organization.

Kapor Capital is an Oakland-based venture capital firm investing in early-stage technology companies that close gaps in access and opportunity for historically underserved communities. The firm backs founders building scalable businesses that improve outcomes across education, healthcare, financial services, workforce development, housing, food systems, and justice. Kapor Capital combines venture investing with a strong commitment to diversity, equity, and inclusion, supporting entrepreneurs whose products and services create measurable social and economic impact while generating venture-scale returns.

Oncology Ventures is a healthcare-focused venture capital firm investing in commercially validated startups transforming cancer care through data, technology, artificial intelligence, and healthcare infrastructure innovation. Founded by cancer survivor Ben Freeberg, the firm focuses on solving systemic challenges across the oncology ecosystem, from early detection and diagnostics to patient navigation, care delivery, and survivorship. The firm backs companies building the non-drug infrastructure of cancer care, helping improve outcomes, reduce inefficiencies, and increase access to evidence-based treatment for patients across the healthcare system.

Pay it Forward Ventures (PIF) builds better lives for billions by investing in source-solving rather than symptom-solving. They fund and found ventures that create new paradigms across financial technology, health, energy, and digital infrastructure — and donate 20% of GP profits to philanthropy because they believe in paying it forward.

T1D Fund is the world's first scaled venture fund dedicated exclusively to type 1 diabetes, operating as an impact investment fund that supports promising companies through equity investments and expertise. They focus specifically on accelerating treatments, prevention, and cures for the approximately 9 million people living with T1D globally. The fund operates as a powerful platform for collaboration, using catalytic capital and expertise to de-risk investments and create a flywheel effect that attracts other investors to the T1D space. As a wholly owned, not-for-profit independently run subsidiary of Breakthrough T1D, they leverage their intellectual capital and expert network to offer comprehensive support to portfolio companies, steering them through regulatory, clinical, and commercial milestones. With over $200 million in assets under management and 25+ active portfolio companies, T1D Fund creates significant impact in the diabetes ecosystem by reinvesting 100% of returns to propel continuous progress. Their unique position as subject matter experts combined with access to Breakthrough T1D's extensive network of research, clinical, and medical expertise enables them to transform the landscape of T1D investment and accelerate the development of life-changing therapies.